MAPT and Alzheimer disease: The aim of this study was to explore associations between CSF biomarkers describing a range of pathophysiological mechanisms including amyloid pathology (Aβ38, Aβ40, Aβ42, ratio Aβ42/Aβ40, sAPPα, sAPPβ), tau pathology (T-tau, P-tau), astrocytic activation (MCP-1) as well as axonal degeneration (NFL) and the core symptomatology of iNPH accessed by the iNPH scale as well as a number of single clinical measures, and to evaluate whether these biomarkers could predict the clinical outcome after shunt surgery in iNPH patients and also in the AD pathology negative patients.